undamentalytics Newsletter
Sign in

Maplight Therapeutics, Inc. (MPLT) stock

Add to watchlist

Add holding +

NASDAQ: MPLT Nasdaq Biotechnology Next results ~November 12, 2026

Maplight Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders4 buying, 8 selling10 purchases and 145 sales by directors and officers, last 12 monthsInsider trades
  • Funds54 adding, 40 cuttingOf 22 active managers that changed their stake, 13 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Next results ~November 12, 2026 (estimated)

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Maplight Therapeutics, Inc.'s latest figures clears our strength thresholds.

Things to watch

  • Volatile shares. Over the past year the shares showed annualised volatility of 112% and a beta of 1.0 against the S&P 500.
  • Heavily shorted. 10.3% of the shares available to trade are sold short (6.8 days of average volume to cover).
  • Missing expectations. Earnings per share fell short of the consensus estimate in 4 of the last four quarters.

Latest results

Earnings per share
-$1.32 against an average estimate of -$1.31: missed by 1.0%
Share reaction
+3.3% in the first session after the results on August 13, 2026, against +0.5% for the S&P 500
Next report
November 12, 2026; average EPS estimate -$1.11

Maplight Therapeutics' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-10.6%
  • 1 week-11.5%
  • 1 month-31.0%
  • This year-61.4%
  • 1 year-59.9%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Earnings

Last results
August 13, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Insider trade
  2. Results
  3. Insider trade
  4. Insider trade
  5. Announcement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Maplight Therapeutics, Inc. valuation models and calculator

No model value for Maplight Therapeutics, Inc. at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: limited reported history: available models are shown without a Buy/Hold/Sell rating.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 12, 2026, after the close. Analysts expect revenue of $0 and EPS of −$1.11 (range −$1.36 to −$0.58) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$4.49 +76% — 0%
Next −$3.42 +24% $15m 0%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −10.8% on 90 days ago. In the last 30 days, 5 analysts raised Maplight Therapeutics, Inc.'s forecast and 0 cut it.

Consensus EPS forecast Maplight Therapeutics, Inc., last 90 days
−$6.00 −$4.00 −$2.00 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$5.03 Current fiscal year, 60 days ago: −$4.60 Current fiscal year, 30 days ago: −$4.64 Current fiscal year, 7 days ago: −$4.70 Current fiscal year, Now: −$4.49 −$4.49 Next fiscal year, 90 days ago: −$3.67 Next fiscal year, 60 days ago: −$3.34 Next fiscal year, 30 days ago: −$3.30 Next fiscal year, 7 days ago: −$3.42 Next fiscal year, Now: −$3.42 −$3.42

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$5.03−$3.67
60 days ago −$4.60−$3.34
30 days ago −$4.64−$3.30
7 days ago −$4.70−$3.42
Now −$4.49−$3.42

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$1.31 −$1.32 −1.0%
Mar 2026 −$1.09 −$1.34 −22.9%
Dec 2025 −$0.83 −$2.47 −197.6%
Sept 2025 −$1.73 −$37.18 −2055.4%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

15 analysts, Oct 2026
Buy1280%
Hold320%
Sell00%

Monthly trend

  1. Oct 202611315
  2. Sep 2026111214
  3. Aug 2026112114

Counts of recommendations published by analysts covering Maplight Therapeutics, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
10.3%
of tradable shares
Days to cover
6.85
at average volume
Short interest, 1 month
+1%
to October 15, 2026
Held by institutions
49%
of shares
Held by insiders
52.2%
of shares
Employees
133
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 2026 to date
Return
MPLT−61%
Industry peers (median)−26%
S&P 500+11%
Months that ended higher
MPLT36%
S&P 50046%
Largest fall from a high during the year
MPLT−83%
S&P 500−9%

Worst fall since October 27, 2025: 83% from July 9, 2026 to November 2, 2026. Getting back needed a 487% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$6.78 – $39.80
From 52-week high
−83.0%
vs 50-day average
−34.6%
vs 200-day average
−66.9%
Volatility (1 year)
112%
Beta vs S&P 500
1.02

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
4 up, 1 down
typical move ±6.4%
After a week
2 up, 3 down
typical move ±8.5%
After a month
4 up, 1 down
typical move ±19.6%
Results releasedNext dayS&P 500 next day5 days21 days
August 13, 2026 +3.3% +0.5% −1.3% +15.6%
May 14, 2026 −6.3% −0.4% −4.5% −8.8%
March 26, 2026 +2.3% −3.5% +16.7% +68.9%
January 9, 2026 +10.9% +0.8% −1.1% +4.1%
December 4, 2025 +9.3% +0.3% +18.8% +0.5%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms . Generated November 3, 2026. Definitions in our methodology.

Who owns it

Funds buying and selling
Reported value
$941M
Institutions reporting
105
Shares held vs prior quarter
▲ 5.9%
Positions opened / closed
34 / 10

Top buyers and sellers, Q2 2026: 54 institutions bought and 40 sold ; the biggest buyer was Price T Rowe Associates Inc (+1.3M shares) and the biggest seller Vestal Point Capital, LP (−420K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Novo Holdings A/S $132M 3.7M 14.0% 0.0%
Fcpm Iii Services B.V. $116M 3.2M 12.3% 0.0%
T. Rowe Price Investment Management, Inc. $99.7M 2.8M 10.6% ▼ 0.7%
Goldman Sachs Group Inc $69.8M 1.9M 7.4% ▼ 2.3%
Price T Rowe Associates Inc $51M 1.4M 5.4% ▲ 1162.5%
Blackrock, Inc. $36.7M 1.0M 3.9% ▼ 23.5%
Nan Fung Group Holdings Ltd $34.8M 971K 3.7% 0.0%
5Am Venture Management, LLC $34M 950K 3.6% 0.0%
Sanofi $32.7M 912K 3.5% 0.0%
State Street Corp $30.5M 852K 3.2% ▲ 151.3%
FMR LLC $29.5M 824K 3.1% ▲ 302.7%
Vanguard Capital Management LLC $28.1M 784K 3.0% ▲ 8.9%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Maplight Therapeutics, Inc.'s complete shareholder register. Values are as reported by the filers ; 2 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $66.2M 10 trades by 4 insiders, last 12 months Insider sales History → $30.2M 145 trades by 8 insiders · 66% under pre-set plans
Net ▲ $36M net buying
Insider Date Trade Shares Price Value
Kroeger Christopher A. Chief Executive Officer October 15, 2026 Sell 73,691 $8.08 $595,423
Foff Erin Pennock Chief Medical Officer October 15, 2026 Sell 15,355 $8.08 $124,068
Hanson Kristopher General Counsel October 15, 2026 Sell 9,020 $8.08 $72,882
Lillie James Woodruff Chief Scientific Officer October 15, 2026 Sell 11,513 $8.08 $93,025
Gillis Jonathan CAO and Interim CFO October 15, 2026 Sell 10,167 $8.08 $82,149
Kreitzer Anatol Chief Discovery Officer October 15, 2026 Sell 12,248 $7.84 $96,024
Hanson Kristopher General Counsel September 16, 2026 Sell pre-set plan 16,509 $11.67 $192,660
Catalyst4, Inc. 10% owner August 14, 2026 Buy 4,400,000 $11.38 $50.1M
Lillie James Woodruff Chief Scientific Officer August 3, 2026 Sell pre-set plan 22,082 $12.54 $276,908
Catalyst4, Inc. 10% owner July 30, 2026 Buy 1,000,000 $13.00 $13M
Catalyst4, Inc. 10% owner July 29, 2026 Buy 3,000 $12.63 $37,890
Cox Troy Director July 28, 2026 Buy 15,620 $9.52 $148,702

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

  • August 13, 2026
  • May 14, 2026
  • March 26, 2026
  • January 9, 2026
  • December 4, 2025

Recent SEC filings

Data status

When each part of this page on Maplight Therapeutics, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Maplight Therapeutics, Inc. in brief

What does Maplight Therapeutics, Inc. do?
Maplight Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Maplight Therapeutics, Inc.'s stock ticker?
Maplight Therapeutics, Inc. trades under the ticker MPLT on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are Maplight Therapeutics, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Novo Holdings A/S, Fcpm Iii Services B.V. and T. Rowe Price Investment Management, Inc. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Are insiders buying or selling Maplight Therapeutics, Inc. stock?
Over the last 12 months, Maplight Therapeutics, Inc.'s directors and officers reported 10 open-market purchases and 145 sales on Form 4. The insider trading page charts every trade.
When is Maplight Therapeutics, Inc.'s next earnings date?
Around November 12, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Maplight Therapeutics, Inc. announces its own schedule.